Cerebral Edema in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis
Authors:
- Daniel StrbianDSDaniel Strbian
- Atte MeretojaAMAtte Meretoja
- Markku KasteMKMarkku Kaste
- Turgut TatlisumakTTTurgut Tatlisumak
- for the Helsinki Stroke Thrombolysis Registry GroupFGfor the Helsinki Stroke Thrombolysis Registry Group
- 9 March 2012
- journal article
- research article
- Published by SAGE Publications in International Journal of Stroke
- Vol. 8 (7) , 529-534
Abstract
Background: Cerebral edema (CED) deteriorates outcome of ischemic stroke patients, and there is no effective medical treatment. Limited data exist on cerebral edema after stroke thrombolysis. Aims: We aimed to analyze impact of cerebral edema on the outcome of thrombolysis-treated patients. Methods: Our cohort included 943 thrombolysis-treated ischemic stroke patients at the Helsinki University Central Hospital (1995–2008). Cerebral edema represented focal brain swelling up to 1/3 (CED-1) or greater than 1/3 (CED-2) of the hemisphere, or midline shift (CED-3). We studied baseline parameters associated with development of cerebral edema and association of cerebral edema with three-month outcome (modified Rankin Scale, mRS). Results: On control imaging, CED-1 was present in 167 (17·7%), CED-2 in 40 (4·2%), and CED-3 in 53 (5·6%) patients. Compared with patients without edema ( n = 683), patients with cerebral edema had higher baseline National Institutes of Health Stroke Scale scores, more often hyperdense cerebral artery sign or early infarct signs on admission computerized tomography, and received thrombolysis later. Cerebral edema was independently associated with poor outcome (mRS 3–6) and mortality, whereas favorable outcome (mRS 0–2) was observed in 77 (46%), 5 (13%), and 3 (6%) patients with CED 1, 2, and 3, respectively. Anti-edema treatment was considered necessary and administered to 49/260 (19%) patients; only five had favorable outcome. Conclusions: Cerebral edema is frequent (28%) among thrombolysis-treated ischemic stroke patients, occurring in severe forms in 10%. Higher baseline National Institutes of Health Stroke Scale, presence of hyperdense cerebral artery sign or early infarct signs, and longer treatment delays are associated with edema development. Edema is a strong independent predictor of three-month outcome. Effect of anti-edema treatment was modest.Keywords
This publication has 28 references indexed in Scilit:
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trialsThe Lancet Neurology, 2007
- Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational studyThe Lancet, 2007
- Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness StudyCanadian Medical Association Journal, 2005
- Ischaemic brain oedemaJournal of Clinical Neuroscience, 2002
- Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom OnsetJAMA, 1999
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- 'Malignant' Middle Cerebral Artery Territory InfarctionArchives of Neurology, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995